CD8A and neoplasm: The decision of evaluating nintedanib combined with immunotherapy was, in part, based on encouraging data suggesting that this TKI does not induce a significant myelosuppression nor affect the tumor infiltration of CD8+ T cells, in contrast to sunitinib (our unpublished observations, Fig. 4e).